Your browser doesn't support javascript.
loading
Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Teng, Wei; Lin, Chen-Chun; Su, Chung-Wei; Lin, Po-Ting; Hsieh, Yi-Chung; Chen, Wei-Ting; Ho, Ming-Mo; Wang, Ching-Ting; Chai, Pei-Mei; Hsieh, Jason Chia-Hsun; Lin, Chun-Yen; Lin, Shi-Ming.
Affiliation
  • Teng W; Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center Taiwan.
  • Lin CC; College of Medicine, Chang Gung University Taiwan.
  • Su CW; Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center Taiwan.
  • Lin PT; College of Medicine, Chang Gung University Taiwan.
  • Hsieh YC; Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center Taiwan.
  • Chen WT; College of Medicine, Chang Gung University Taiwan.
  • Ho MM; Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center Taiwan.
  • Wang CT; College of Medicine, Chang Gung University Taiwan.
  • Chai PM; Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center Taiwan.
  • Hsieh JC; College of Medicine, Chang Gung University Taiwan.
  • Lin CY; Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center Taiwan.
  • Lin SM; College of Medicine, Chang Gung University Taiwan.
Am J Cancer Res ; 12(4): 1899-1911, 2022.
Article in En | MEDLINE | ID: mdl-35530282
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline / Prognostic_studies / Risk_factors_studies Language: En Journal: Am J Cancer Res Year: 2022 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline / Prognostic_studies / Risk_factors_studies Language: En Journal: Am J Cancer Res Year: 2022 Document type: Article Country of publication: